Muscoflex

Quick links to important sections

Muscoflex

Method of action: Muscle Relaxant

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Muscoflex

Property Description
Active ingredient Thiocolchicoside (INN)
Forms Capsules, Tablets, Solution for Injection, Cream, Gel
Pharmacological class Centrally acting muscle relaxant (Spasmolytic)
Common purpose Reduction of muscle tone and associated stiffness
Origin Semi-synthetic (derivative of colchicine)

What Type of Drug is Muscoflex (Thiocolchicoside)?

Muscoflex is primarily identified as a medicinal agent belonging to the class of centrally acting muscle relaxants, a category of drugs whose principal function is the alleviation of painful and excessive muscle tone. The core therapeutic agent is Thiocolchicoside, the official International Nonproprietary Name (INN). Thiocolchicoside is recognized as a specific spasmolytic agent used in managing acute muscle contractures. This classification means the medicine is intended to target the stiffness itself.

This medicine exerts its effects within the central nervous system (CNS), modulating the spinal cord pathways that regulate motor reflexes and involuntary muscle contraction. The primary role of Muscoflex is to address muscle tension through central nervous pathways.

Composition, Origin, and Available Forms

The definitive composition of Muscoflex centers on Thiocolchicoside, which is classified as a semi-synthetic derivative of the naturally occurring glucoside colchicine. This modification grants the derivative specific myorelaxant properties distinct from the original substance. Muscoflex is a single-ingredient product, containing only Thiocolchicoside as the active pharmaceutical ingredient. It is supplied in various dosage forms, including capsules and tablets for oral intake, a solution for injection for intramuscular administration, and cream or gel for topical application, ensuring flexibility in delivery method.

General Purpose and Benefit (Muscle Relaxation)

The general purpose of Muscoflex is directly linked to the reduction of excessive muscle tone and the mitigation of rigidity associated with painful muscle spasms. By centrally inhibiting the mechanisms that sustain involuntary muscular contraction, the agent helps to normalize heightened muscle rigidity. The use of Thiocolchicoside is directed toward the reduction of pain intensity and improved functional outcomes. The subsequent relaxation of the muscle spasm contributes to a secondary, associated analgesic property, easing the pain caused by the underlying mechanical tension.

What side effects are possible with Muscoflex?

Possible Side Effects and Safety Information

The safety profile of Muscoflex (Thiocolchicoside) is documented in official regulatory sources, classifying adverse reactions by frequency and potential severity. This information strictly details the possible risks without providing advice or instructions for use.


Documented Adverse Reactions

The side effects are organized by the system or organ affected and their expected frequency, as defined by regulatory bodies.

Frequency Category Examples of Adverse Reactions (by System)
Common (ge 1/100 to <1/10) Gastrointestinal (Diarrhoea, Stomach pain), Nervous System (Drowsiness/Somnolence)
Uncommon (ge 1/1,000 to <1/100) Gastrointestinal (Nausea, Vomiting), Skin (Pruritus, Erythema)
Rare (ge 1/10,000 to <1/1,000) Immune System (Urticaria/Hives)
Not Known Immune System (Anaphylactic Shock, Angioedema), Nervous System (Seizure or relapsed attack), Hepato-biliary (Fulminant Hepatitis)

Serious Safety Restrictions

Official labeling contains specific constraints related to the drug's safety profile:

  • Genotoxicity Risk: A metabolite of Thiocolchicoside is linked to aneuploidy (abnormal chromosome number), which is a risk factor for teratogenicity and potentially impaired fertility. This risk mandates that use must be limited to the shortest duration and lowest dose, and long-term use must be avoided.
  • Contraindications for Specific Populations: Muscoflex is strictly contraindicated during pregnancy and lactation. It is also contraindicated for use in children and adolescents under 16 years of age.
  • Seizure Precaution: Caution is required in patients with a history of epilepsy or a risk of seizures; treatment must be discontinued immediately if a seizure occurs.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents for Muscoflex (Thiocolchicoside) define the overdose profile primarily through specific documented manifestations and mandated emergency response protocols.

The most frequently documented clinical manifestations of an overdose are digestive signs, specifically including diarrhoea and vomiting. In the event of an accidental ingestion of a dose higher than the normal amount, the mandated action is to seek monitoring by a physician immediately.

The officially defined treatment approach is restricted to symptomatic and supportive treatment, as regulatory constraints confirm that no specific antidote is known for the active substance. Procedures described in the management of overdose include the administration of activated charcoal and potentially inducing gastric emesis to reduce further absorption, particularly if a very large quantity has been taken. It is also explicitly stated that intensive elimination procedures, such as haemodialysis or forced diuresis, are documented as not useful. This structure emphasizes that the required response is focused on rapid professional evaluation and dedicated physiological support by a healthcare provider, and continued physician monitoring is explicitly required after over-exposure.

Therapeutic Uses of Muscoflex

What Muscoflex Treats: Main Uses and Benefits

Muscoflex is commonly used to help with symptoms related to physical discomfort associated with acute musculoskeletal conditions. It is relevant when short-term symptomatic assistance is needed, providing supportive relief that may assist patients with managing difficult episodes.

The medication is used to address symptoms of muscle spasm.

Key Therapeutic Domains

Muscoflex is applied across domains where additional symptomatic support is needed, in situations where patients experience symptoms that become more disruptive during flare-ups.

The medication is relevant for easing symptoms that interfere with daily functioning. It is commonly used across conditions presenting with acute episodes. Its symptomatic relief may help with managing manifestations such as:

  • pain
  • tenderness

“It is used in areas where short-term symptom management is appropriate, applied during phases of increased distress or discomfort.”

Patient Benefit

This support contributes to easing the overall symptom load and assists with maintaining functional stability. It offers symptomatic relief that helps patients cope with symptom fluctuations and supports patients during episodes of heightened discomfort.

Quick Fact: Relief for Acute Muscle Spasm

Regulatory References

  1. NIH DailyMed official labeling

Eligibility and Restrictions for Use

Who Can and Cannot Use Muscoflex?

The population eligibility for Muscoflex (Thiocolchicoside) is strictly defined by regulatory authorities and is not based on self-assessment. Use is primarily restricted to adults and older adolescents.

Official Eligibility and Contraindications

The following table summarizes the official regulatory status for key populations:

Population Group Eligibility Status Regulatory Basis
Adults (18+ years) Eligible Standard Use
Adolescents (16+ years) Eligible Established Age Limit
Children (<16 years) Contraindicated Safety Concerns
Pregnant Women Contraindicated Genotoxicity Risk
Breastfeeding Women Contraindicated Secretion into Milk

Restrictions and Required Precautions

Muscoflex is contraindicated for patients with a known hypersensitivity to the active ingredient or excipients. Its use is also prohibited for women of childbearing potential who are not utilizing highly effective contraception.

Conditional use is required for patients with a history of epilepsy or an increased risk of seizures. Treatment must be discontinued immediately if a seizure occurs. Additionally, oral forms containing lactose are restricted for patients with rare hereditary metabolic disorders like galactose intolerance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Muscoflex (Thiocolchicoside) outlines interaction patterns based on additive pharmacological effects and toxicological outcomes, rather than specific pharmacokinetic mechanisms.

Interactions Affecting Central Nervous System Function:

Co-administration with other skeletal muscle relaxants is officially not recommended in regulatory documents due to the potential for an additive spasmolytic effect and an increased overall impact on the muscular-skeletal system. Furthermore, the consumption of alcohol (ethanol) must be avoided because of the officially documented risk of increased drowsiness (somnolence), which reflects a pharmacodynamic reinforcement of the central depressant effect.

Documented Organ Toxicity and Analgesics:

Regulatory surveillance notes an official association between the use of Thiocolchicoside and co-administration of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or Paracetamol. This combination is linked to post-market reports of serious liver conditions (fulminant hepatitis), suggesting a potential for officially recognized additive organ toxicity.

Population-Specific Regulatory Restrictions:

A critical restriction is cited for women of childbearing potential who are not using effective contraception; this population is officially contraindicated due to the aneugenic potential of the metabolite, SL59.0955. This constraint is defined by regulatory bodies based on the metabolite's inherent risk. No mandatory timing separation rules for co-administration with other products are stated in official regulatory documentation.

Mechanism of Action

Muscoflex exerts its effects by engaging multiple distinct biochemical pathways.

Targeting Prostaglandin Synthesis Inhibition

This domain involves the action of the Non-Steroidal Anti-Inflammatory Drug (NSAID) component, which acts within the cyclooxygenase (COX) enzyme-mediated signaling pathway. It inhibits the biosynthesis of prostaglandins, molecules that function as key messengers in the cascade leading to local inflammatory signaling. The subsequent physiological consequence is the attenuation of downstream inflammatory mediator activity.


Influencing Central Nociceptive Pathways

This aspect relates to the analgesic and antipyretic component (e.g., Paracetamol/Acetaminophen). This mechanism is thought to engage central pathways, potentially by influencing descending serotonergic inhibitory pathways or by regulating specific prostaglandin synthesis in the central nervous system. This action influences the regulation of transmitter kinetics and may affect signaling processes associated with nociception.


Proteolytic and Microcirculatory Modulation

This domain is addressed by the proteolytic enzymes (e.g., Trypsin, Bromelain) and antioxidant components (e.g., Rutoside) found in some formulations. These agents act on systemic and local biological processes by assisting in the hydrolysis of abnormal proteins at the site of inflammation. This modification of molecular steps alters microcirculatory parameters and influences the local biochemical environment, leading to observable changes in tissue dynamics.

Dosage and Administration Information

How to Use Muscoflex

The administration of Muscoflex (Thiocolchicoside) involves specific routes, maximum doses, and time limits for treatment. The medicine is available for both oral intake (as capsules or tablets, such as 8 mg strength) and intramuscular (IM) injection (typically a 4 mg solution for injection).


Administration Guidelines

Administration scope Detail
Route of administration Oral (tablets/capsules) and Intramuscular (solution for injection).
Dosing schedule The maximum total daily dose is 16 mg for the oral route, administered as 8 mg twice daily. The maximum total daily dose for the IM route is 8 mg, administered as 4 mg twice daily.
Age-group rules Systemic use is restricted to individuals 16 years of age and older.
Special procedural conditions The total daily dose must be administered in two equal doses. Oral forms are swallowed with water. In case of diarrhea, the dose is reduced or ingested with an antacid.

Use-Context Constraints and Duration

Muscoflex is intended for strictly short-term use, and the treatment course is not extended beyond defined limits. Systemic doses are split and administered every 12 hours.

  • Oral Treatment: Maximum duration is 7 consecutive days.
  • IM Treatment: Maximum duration is 5 consecutive days.

These usage constraints define the methods and maximum duration for administering the medicine.

Recent Clinical Evidence

Research evidence / Overview of Studies for Muscoflex


Evidence for Use in Acute Muscle Spasms

The active ingredient in Muscoflex was studied in research examining conditions characterized by fluctuating or episodic manifestations, particularly painful muscle spasms and contractures often linked to spinal issues, such as acute low back pain. Researchers used Randomized Controlled Trials (RCTs) to explore how symptoms change over time, and the drug was evaluated in comparison against both inactive and other common pain-relieving treatments.

These studies primarily examined outcomes related to physical discomfort, tracking changes in patient-reported pain intensity scores over short periods. Research also explored outcomes reflecting daily functioning or activity level, as well as objective measures of muscle stiffness. Other findings describe patterns observed in the studies where researchers monitored changes in muscle stiffness and overall patient experience.


Comparing Muscoflex to Placebo and Other Treatments

The available evidence base contains trials that were evaluated in settings comparing the active ingredient directly against a placebo (an inactive substance). Other research examined the drug when it was evaluated in combination with standard treatments, such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Studies of combination use reported how symptoms evolved in the observed populations when the drug was used in research exploring short-term symptom changes alongside other medication. However, the evidence for its effect when it was evaluated in single treatment (monotherapy) remains limited, which is a research gap often cited when interpreting overall findings.


Study Quality and Short-Term Follow-up

The observation periods in the available studies are generally short, a feature consistent with the short-term outcomes that research examines in painful muscle contractures. Most trials monitored patient responses over defined time intervals lasting between three and seven days.

Reviews of the collected trials data show patterns related to high variability in study design, and the evidence quality varies across studies, with reviewers citing limitations such as methodological issues or high risk of bias. Furthermore, reviews of pooled analysis findings describe patterns where the size of the effect on pain reduction was cited as small relative to the Minimally Important Difference (MID).


What Remains Uncertain and Research Gaps

Several key limitations and evidence gaps exist in the current research. Follow-up durations were limited in nearly all studies, meaning long-term effects are not fully established regarding whether any observed changes in outcomes reflecting daily functioning are durable.

The certainty surrounding the clinical implications of the findings is constrained by the methodological issues and the small size of the reported effect estimates. Finally, the available research focusing on the drug as a monotherapy (used alone) remains limited relative to the available evidence for its combination use. This research highlights what is known — and what is still uncertain about how the drug was evaluated in research settings.

Key Studies & References Efficacy and Safety of the Combination of Diclofenac and Thiocolchicoside in the Treatment of Low Back Pain and Other Conditions: Systematic Review of the Literature

Frequently Asked Questions (FAQ)

Common questions about Muscoflex (FAQ)


Q: Is Muscoflex a type of painkiller?

Muscoflex is officially classified as a centrally acting muscle relaxant or spasmolytic agent. Its primary purpose is to reduce excessive muscle tone and rigidity. The medicine is associated with a secondary analgesic property, meaning it helps ease the pain that is caused by the underlying muscle tension, but it is not classified primarily as a conventional painkiller.


Q: Does Muscoflex interact with common over-the-counter medicines?

Official regulatory documents specifically caution about co-administration with other analgesics such as Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Paracetamol. This combination is cited due to post-market reports suggesting a potential for officially recognized additive organ toxicity, particularly affecting the liver.


Q: Can Muscoflex affect my ability to drive?

According to the official product information, drowsiness (somnolence) is listed as a common adverse reaction. Since this is a central nervous system effect, it has the potential to affect mental alertness. This effect may influence the ability to safely perform tasks that require mental alertness, such as operating machinery or driving.


Q: Why do some people say Muscoflex didn't work for them?

Research findings describe patterns where studies examining the drug showed variability in results. Reviewers have cited limitations, noting that the size of the drug's effect on pain reduction was sometimes cited as small compared to the Minimally Important Difference (MID). This variability in research findings may contribute to different patient experiences regarding the drug's perceived effect.


Q: How is Muscoflex different from other treatments for similar conditions?

Muscoflex is classified as a centrally acting muscle relaxant (spasmolytic). This means its action involves modulating pathways within the central nervous system, specifically the spinal cord, to regulate involuntary muscle contraction. This mechanism of addressing muscle tension through the central nervous pathways distinguishes it from treatments that act solely at the muscle level.


Q: Can older adults safely use Muscoflex?

Official regulatory documents state the drug is approved for use in adults, meaning individuals aged 18 years and older. However, the regulatory documentation does not define specific restrictions or special precautions that are unique to the 'older adult' demographic compared to the general adult population.


Q: What food or drinks should I avoid while taking Muscoflex?

Regulatory documents explicitly state that the consumption of alcohol (ethanol) must be avoided during treatment. This restriction is due to the documented risk of increased drowsiness, which is a reinforcement of the drug's central depressant effect. No specific restrictions are cited in official documentation regarding other foods.


Q: Can Muscoflex cause dizziness?

Official safety information lists drowsiness (somnolence) as a common side effect of the medicine, which is a central nervous system effect. The official safety information does not explicitly list dizziness as an adverse reaction, but the listed effect of drowsiness is a central nervous system effect.


Q: How long does the effect of one dose of Muscoflex last?

Official regulatory guidelines for systemic use specify that the total daily dose must be split into two equal doses and administered every 12 hours. This administration schedule is consistent with the drug's properties and the defined time limits for its administration.


Q: Does Muscoflex help with all types of pain?

The general purpose of the medicine is to address the reduction of muscle tone and rigidity associated with painful muscle spasms. The associated analgesic property is secondary to this primary action. Therefore, its role in pain relief is specifically linked to the easing of pain caused by underlying mechanical tension from muscle stiffness.


Q: Is Muscoflex used for conditions other than those listed in the main uses?

Regulatory authorities strictly define the purpose of Muscoflex. It is intended only for the reduction of excessive muscle tone and mitigation of rigidity associated with painful muscle spasms, as detailed in the official product information.


Q: Does Muscoflex need to be taken with food?

Official administration guidelines state that oral forms must be swallowed with water. Regulatory advice also suggests that in the case of experiencing diarrhea, one may consider ingesting the dose with an antacid. Taking the medicine with food is not explicitly required or prohibited in the official documents.


Q: Are there any specific safety classifications or boxed warnings for Muscoflex?

Official labeling contains Serious Safety Restrictions based on the potential risks of the active ingredient's metabolite. These restrictions, which include the mandated requirement to limit use to the shortest duration and lowest dose due to genotoxicity risk, are similar to the information communicated in formalized drug warnings.


Q: What does 'mechanism of action' mean for Muscoflex?

The term 'mechanism of action' describes the way the medicine works in the body. For Muscoflex, this involves modulating specific spinal cord pathways that regulate motor reflexes. Official documents classify it as a centrally acting muscle relaxant because it targets these central pathways to reduce muscle tension.


Q: Are there any specific symptoms that mean I should not take Muscoflex?

Official documents state that the medicine is contraindicated for patients with a known hypersensitivity (allergic reaction) to the active ingredient. Additionally, regulatory guidance emphasizes that treatment must be immediately discontinued if a seizure occurs during the course of use.


Q: What are the potential mental side effects of Muscoflex?

Official regulatory documents list adverse reactions related to the central nervous system. These include common effects such as drowsiness (somnolence) and more rare, serious events such as seizure or relapsed attack. No other specific cognitive or psychological effects are explicitly listed in the official safety profile.


Q: What does the patient leaflet say about taking Muscoflex with other medicines?

Information derived from official regulatory documents indicates that co-administration with other skeletal muscle relaxants is officially not recommended. Precautions are also cited regarding use alongside other analgesics like NSAIDs and Paracetamol due to the potential for additive organ toxicity.


Q: What research evidence exists about Muscoflex's performance over time?

Research evidence indicates that studies examining Muscoflex performance typically monitored patient responses over very short durations, usually between three and seven days. Because of these short observation periods, regulatory reviews have noted that long-term effects related to durability of functional outcomes are not fully established.


Q: What if I experience a rare or unexpected side effect from Muscoflex?

Official safety information documents all reported reactions, including those listed with a 'Not Known' frequency category, such as Anaphylactic Shock or Fulminant Hepatitis. This information is meant to inform patients about the range of documented adverse events.


Q: Why does my doctor prescribe Muscoflex?

Regulatory documents classify Muscoflex as a centrally acting muscle relaxant (spasmolytic). This classification indicates it is intended to address conditions characterized by painful and excessive muscle tone, such as acute muscle spasms and contractures linked to spinal issues.


Q: Can Muscoflex be crushed or split?

Official administration rules for oral forms specify that the medicine must be swallowed with water. However, the regulatory documents do not explicitly provide instruction, prohibition, or commentary regarding the physical modification of the tablet or capsule, such as crushing or splitting.


Q: Why is Muscoflex sometimes prescribed to athletes?

The general purpose of Muscoflex is defined in regulatory documents as the reduction of excessive muscle tone and rigidity. Since these painful muscle spasms and contractures can affect any patient, including those involved in physical activity, the medicine is intended to address these specific symptoms.

How should Muscoflex be stored and disposed of?

Official Storage and Disposal Requirements

Muscoflex must be stored and handled strictly according to the official instructions detailed on the product label and regulatory documents. These requirements are established to maintain the medicine's stability and prevent unauthorized access.

Storage Conditions

Requirement Specification
Temperature Store below 30 C or between 10 C and 25 C in a cool, dry place.
Protection Protect the medicine from both moisture and light.
Packaging Keep the medicine in its original container and ensure the container or pack is tightly closed.
Child Safety Store strictly out of the sight and reach of children and pets.

Disposal Rules

Regulatory instructions mandate that any unused Muscoflex must be safely disposed of. Disposal should prevent the consumption of the medicine by children, pets, or other people. No specific hazardous-waste instructions are generally documented; disposal must follow the general principle of keeping it away from unauthorized access.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Muscoflex found in:

A-Z Index: